ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 27 October 2026 FIRST PATIENT DOSED WITH ALA-101 Highlights: • Arovella achieves major milestone with first patient dosed in its phase 1 clinical trial of ALA-101, Arovella's "off-the-shelf" cell therapy for blood cancers •...